Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -310.94% is 28% below its 2-year average of -242.17%, around the middle of its 2-year range (-845.32%–-57.58%).
As of the fiscal period ended Tuesday, June 30, 2026. 155.84% below its 12-month average of -121.54%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -310.94%.
RETURN ON EQUITY (ROE)
-310.94%
RETURN ON EQUITY (ROE) AVG TTM
-121.54%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-155.84%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-640.16%
vs the sector median at left
Tvardi Therapeutics, Inc.
Market Cap
$10.23M
Return on Equity (ROE)
-310.94%
TTM Avg
-121.54%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$10.11M
Return on Equity (ROE)
N/A
TTM Avg
18596.99%
3Y Avg
9182.42%
5Y Avg
7349.85%
Market Cap
$10.10M
Return on Equity (ROE)
-252.37%
TTM Avg
-195.20%
3Y Avg
-116.68%
5Y Avg
-90.09%
Market Cap
$10.41M
Return on Equity (ROE)
-57.34%
TTM Avg
-65.47%
3Y Avg
-124.96%
5Y Avg
28.05%
Market Cap
$9.88M
Return on Equity (ROE)
-157.76%
TTM Avg
-137.97%
3Y Avg
-196.09%
5Y Avg
-89.86%
Market Cap
$10.45M
Return on Equity (ROE)
N/A
TTM Avg
-652.54%
3Y Avg
-364.25%
5Y Avg
-252.47%
Market Cap
$10.41M
Return on Equity (ROE)
N/A
TTM Avg
-43.97%
3Y Avg
-160.70%
5Y Avg
-188.29%
Market Cap
$9.73M
Return on Equity (ROE)
-189.76%
TTM Avg
-774.75%
3Y Avg
-460.85%
5Y Avg
-442.56%
Market Cap
$10.37M
Return on Equity (ROE)
N/A
TTM Avg
-22.56%
3Y Avg
-244.57%
5Y Avg
3710.91%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | $10.23M | -310.94% | -121.54% | N/A | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.11M | N/A | 18596.99% | 9182.42% | 7349.85% |
| Lifeward Ltd. (LFWD)vs › | $10.10M | -252.37% | -195.20% | -116.68% | -90.09% |
| Satellos Bioscience Inc. (MSLE)vs › | $10.41M | -57.34% | -65.47% | -124.96% | 28.05% |
| Valion Bio, Inc. (VBIO)vs › | $9.88M | -157.76% | -137.97% | -196.09% | -89.86% |
| Senti Biosciences, Inc. (SNTI)vs › | $10.45M | N/A | -652.54% | -364.25% | -252.47% |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.41M | N/A | -43.97% | -160.70% | -188.29% |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.73M | -189.76% | -774.75% | -460.85% | -442.56% |
| Polyrizon Ltd. (PLRZ)vs › | $10.37M | N/A | -22.56% | -244.57% | 3710.91% |
| Pluri Inc. (PLUR)vs › | $10.79M | N/A | 216.74% | -5384.23% | -3626.91% |
ROE
-310.9%
ROA
-148.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -310.94% |
| 2026-03-31 | -106.44% |
| 2025-12-31 | -64.65% |
| 2025-09-30 | -68.09% |
| 2025-06-30 | -57.58% |
| 2024-06-30 | -845.32% |
